Introduction {#s1}
============

Dexmedetomidine was approved by the Food and Drug Administration (FDA) at the end of 1999 as a short-term medication (\<24 hours) for analgesia and sedation in mechanical ventilated intensive care unit (ICU) patients. In 2008, the FDA approved a new indication in non intubated patients requiring sedation before and/or during surgical and non-surgical procedures. Dexmedetomidine is a highly selective a2-adrenergic receptor agonist, which binds to transmembrane G protein-binding adrenoreceptors in the periphery (α2A), brain and spinal cord (α2B, α2C) tissues [@pone.0082913-Paris1]. In contrast to other sedative agents, dexmedetomidine, by acting on a2 receptors in the locus caeruleus [@pone.0082913-Huupponen1], has potential analgesic effects [@pone.0082913-Guo1] without respiratory depression [@pone.0082913-Iirola1], [@pone.0082913-Morsch1]. Only one meta-analysis of randomized controlled trials (RCTs) [@pone.0082913-Tan1] was published so far: Tan and Ho reported a reduction in length of ICU stay, but not in duration of time to extubation when dexmedetomidine was compared with alternative sedative agents.

Since several RCTs [@pone.0082913-AbdAziz1]--[@pone.0082913-Khalil1], including two large ones [@pone.0082913-Jakob1], were recently published, and one further RCT [@pone.0082913-Sahin1] was not included in the previous meta-analysis [@pone.0082913-Tan1] we decided to perform an updated meta-analysis of all the RCTs ever performed on dexmedetomidine versus any comparator in the ICU setting to evaluate time to extubation, ICU stay and survival.

Materials and Methods {#s2}
=====================

Search Strategy {#s2a}
---------------

Pertinent studies were independently searched in BioMedCentral, PubMed, Embase, and the Cochrane Central Register of clinical trials (updated February 1^st^ 2013) by four trained investigators. The full PubMed search strategy aimed to include any RCTs ever performed in humans with dexmedetomidine in any clinical setting and is presented in the supplemental material ([Text S1](#pone.0082913.s011){ref-type="supplementary-material"}). In addition, we employed backward snowballing (i.e., scanning of references of retrieved articles and pertinent reviews) and contacted international experts for further studies with no language restriction.

Study Selection {#s2b}
---------------

References were first independently examined at a title/abstract level by four investigators, with divergences resolved by consensus, and then, if potentially pertinent, retrieved as complete articles. The following inclusion criteria were used for potentially relevant studies: random allocation to treatment (dexmedetomidine versus any comparator with no restrictions on dose or time of administration); studies involving patients who required mechanical ventilation in an ICU. The exclusion criteria were duplicate publications (in this case we referred to the first article published while retrieved data from the article with the longest follow-up available), non-adult patients and lack of data on all of the following: ICU stay, time to extubation and mortality. Two investigators independently assessed compliance to selection criteria and selected studies for the final analysis, with divergences resolved by consensus.

Data Abstraction and Study {#s2c}
--------------------------

Baseline, procedural, and outcome data were independently abstracted by four trained investigators ([table 1](#pone-0082913-t001){ref-type="table"} and [table 2](#pone-0082913-t002){ref-type="table"}). If a trial reported multiple comparisons [@pone.0082913-Maldonado1], [@pone.0082913-Ruokonen1], the comparators were aggregated as a single control group. At least two separate attempts at contacting original authors were made in cases of missing data. The co-primary endpoints of the present review were the length of ICU stay (days) and time to extubation (hours from randomization to extubation).

10.1371/journal.pone.0082913.t001

###### Description of the 28 trials included in the meta-analysis.

![](pone.0082913.t001){#pone-0082913-t001-1}

  First author                                       Year           Setting            Dex patients   Control patients       Comparator                                                                                                                           Comparator dose                                                                                                                                           Follow-up
  ------------------------------------------------- ------ -------------------------- -------------- ------------------ --------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------
  Aziz AN [@pone.0082913-AbdAziz1]                   2011       Cardiac surgery             14               14               Morphine                                                                                                                            4.6--46 µg/kg/h                                                                                                                                           24 hours
  Corbett SM [@pone.0082913-Corbett1]                2005       Cardiac surgery             43               46               Propofol                                                                                                                  0.2--0.7 µg/kg/h or 5--75 µg/kg/min                                                                                                                                 ICU stay
  Elbaradie S [@pone.0082913-Elbaradie1]             2004       Major surgeries             30               30               Propofol                                                                                                    Bolus dose of 1 mg/kg followed by an infusion of 0.5--1 mg/kg/h                                                                                               24 hours after commencement of sedative infusions
  Esmaoglu A [@pone.0082913-Esmaoglu1]               2009   Post caesarean eclampsia        20               20               Midazolam                                                                                                  Loading dose of 0.05 mg/kg followed by an infusion of 0.1 mg/kg/h                                                                                                                  ICU stay
  Herr DL [@pone.0082913-Herr1]                      2003       Cardiac surgery            148              147               Propofol                                                                                                                                   NA                                                                                                                                     24 hours after discharge from ICU
  Jakob SM MIDEX [@pone.0082913-Jakob1]              2012             ICU                  249              251               Midazolam                                                                                                                          0.03--0.2 mg/kg/h                                                                                                                                           45 days
  Jakob SM PRODEX [@pone.0082913-Jakob1]             2012             ICU                  251              247               Propofol                                                                                                                            0.3--4.0 mg/kg/h                                                                                                                                           45 days
  Khalil MA [@pone.0082913-Khalil1]                  2012       Cardiac surgery             25               25                Placebo                                                                                         Loading dose 1 µg/kg over 10 minutes followed by a maintenance infusion of 0.5 µg/kg/h                                                                                                     Hospital stay
  Leino K [@pone.0082913-Leino1]                     2011       Cardiac surgery             44               43                Placebo                                                                                39 ml/h for 20 min, 24.5 ml/h for 40 minutes, 14 ml/h for 60 min, 10.5 ml/h for 120 min and then 7 ml/h                                                                                   48 hours after catheter insertion
  Maldonado JR [@pone.0082913-Maldonado1]            2009       Cardiac surgery            4040             3840         Propofol, midazolam                                                                                                     Propofol: 25--50 µg/kg/min; Midazolam: 0.5--2 mg/h                                                                                                                       Hospital stay
  Martin E [@pone.0082913-Martin1]                   2003             ICU                  203              198                Placebo                                                                    1 µg/kg for 10 min (loading dose) and then 0.4 µg/kg/h. The latter rate could be adjusted within the range of 0.2 to 0.7 µg/kg/h                                                                         24 hours from infusion end
  Memis D [@pone.0082913-Memis1]                     2006             ICU                   12               12               Propofol                                                                                                                      2 mg/kg/h over 5-h infusion                                                                                                                                     ICU stay
  Memis D [@pone.0082913-Memi1]                      2007             ICU                   20               20               Midazolam                                                                                             Loading dose of 0.2 mg/kg over 10 min followed by 0.1--0.5 mg/kg/h infusion                                                                                                             ICU stay
  Memis D [@pone.0082913-Memi2]                      2009             ICU                   20               20               Propofol                                                                                              1 mg/kg over 15 min followed by a maintenance dose of 1 to 3 mg/kg per hour                                                                                                             ICU stay
  MendaF[@pone.0082913-Menda1]                       2010       Cardiac surgery             15               15                Placebo                                                                                                                           1 µg/kg in 15 min                                                                                                                                          ICU stay
  Ozkan N [@pone.0082913-Ozkan1]                     2007       Cardiac surgery             20               20               Midazolam                                                                                                                          0.05--0.07 mg/kg/h                                                                                                                                 24 hours post extubation
  Pandharipande PP [@pone.0082913-Pandharipande1]    2007             ICU                   52               51               Lorazepam                                                                                                                           Maximum 10 mg/hr                                                                                                                                          12 months
  Reade MC [@pone.0082913-Reade1]                    2009             ICU                   10               10              Haloperidol                                                                                                   0.5--2 mg/hour preceded by a loading dose of 2.5 mg if desired                                                                                                                 Hospital stay
  Riker RR [@pone.0082913-Riker1]                    2009             ICU                  244              122               Midazolam                                                                                                     Loading dose 0.05 mg/kg then infusion rate 0.02--0.1 mg/kg/h                                                                                                                     30 days
  Ruokonen E [@pone.0082913-Ruokonen1]               2009             ICU                   41               44          Propofol Midazolam    Propofol: 2.4 mg/kg/h for 1 h and then adjusted stepwise at 0.8, 1.6, 2.4, 3.2, and 4.0 mg/kg/h; Midazolam: boluses (1--2 mg), starting at 3 boluses per hour for 1 h, and thereafter 1--4 boluses per h, and if not sufficient as continuous infusion                        45 days
  Sahin N [@pone.0082913-Sahin1]                     2005       Cardiac surgery             15               15               Midazolam                                                                                                           0.1 mg/kg/h intraoperative; 0.5--1 µg/kg/min ICU                                                                                                                   12 hours postoperatory
  Shehabi Y [@pone.0082913-Shehabi1]                 2009       Cardiac surgery            154              152               Morphine                                                                                                                            10--70 µg/kg/ml                                                                                                                                         Hospital stay
  Tasdogan M [@pone.0082913-Tasdogan1]               2009      Abdominal surgery            20               20               Propofol                                                                                                 1 mg/kg over 15 minutes followed by a maintenance dose of 1--3 mg/kg/h                                                                                                                25 days
  Terao Y [@pone.0082913-Terao1]                     2012    Cervical spine surgery         16               16               Propofol                                                                                     0.1 mg/kg/min for 10 minutes as a loading dose, followed by a continuous infusion at 1 mg/kg/h                                                                                                 Hospital stay
  Triltsch AE [@pone.0082913-Triltsch1]              2002             ICU                   15               15                Placebo                                                                                            Loading dose of 6 µg/kg/h 1 for 10 min; maintenance infusion of 0.1--0.7 µg/kg/h                                                                                        24 hours after the end of study drug infusion
  Venn RM [@pone.0082913-Venn1]                      2001        Major surgery              10               10               Propofol                                                                                                      1--3 mg/kg/h after loading dose of up to 1 mg/kg over 10 min                                                                                                                     35 days
  Wan LJ [@pone.0082913-Wan1]                        2011             ICU                  102               98               Midazolam                                                                                                                                  NA                                                                                                                                                 24 hours
  Yao L [@pone.0082913-Yao1]                         2010             ICU                   35               38               Midazolam                                                                                                Loading dose (0.06 mg/kg) and then maintained with 0.04--0.20 mg/kg/h                                                                                                     Time on mechanical ventilation

Dex: dexmedetomidine; ICU: Intensive Care Unit; NA: not available; RASS: Richmond Agitation Sedation Scale; BIS: BispectralIndex ; MAAS: Motor Activity Assessment Scale.

10.1371/journal.pone.0082913.t002

###### Doses, sedation scales and target sedation levels.

![](pone.0082913.t002){#pone-0082913-t002-2}

  First author                                                         Study endpoint                                                                                                                                            Dexmedetomidine dose                                                                                                                                     Start study drug                                                                Stop study drug
  ------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------- -------------------------------------------------------------------------------------------------------------------
  Aziz NA [@pone.0082913-AbdAziz1]                                    Sedation quality                                                                                                                                            0.03--0.25 µg/kg/h                                                                                                                                         ICU arrival                                                                  After 24 hours
  Corbett SM [@pone.0082913-Begg1]                                    Sedation quality                                                                                                                   Loading dose of 1 µg/kg in 15 min, followed by a 0.4/µg/kg/h infusion                                                                                                        During surgery, after CPB          Propofol was discontinued before extubation while dexmedetomidine was continued for up to 1 hour after extubation
  Elbaradie S [@pone.0082913-Elbaradie1]                              Sedation quality                                                                                                                 Loading dose of 2.5 µg/kgin10 min followed by a 0.2--0.5 µg/kg/h infusion                                                                                                             ICU arrival                                                                 Before extubation
  Esmaoglu A [@pone.0082913-Esmaoglu1]                                Sedation quality                                                                                                                    Loading dose of 1 µg/kg in 20 min followed by a0.7 µg/kg/h infusion                                                                                                                ICU arrival                                                                        NA
  Herr DL [@pone.0082913-Herr1]                                       Sedation quality                                                                     Loading dose of 1 µg/kg in20 min followed by a0.4 µg/kg/h infusion. After transfer to the ICU, the infusion rate was titrated in the range of 0.2 to 0.7 µg/kg/h                                                                Sternal closure                                                         6--24 hours after extubation
  Jakob SM MIDEX [@pone.0082913-Jakob1]                               Sedation quality                                                                                                                                             0.2--1.4 µg/kg/h                                                                                                                              Within 72 hours after ICU admission                                                Extubation, 14 days maximum
  Jakob SM PRODEX [@pone.0082913-Jakob1]                              Sedation quality                                                                                                                                             0.2--1.4 µg/kg/h                                                                                                                              Within 72 hours after ICU admission                                                Extubation, 14 days maximum
  Khalil MA [@pone.0082913-Khalil1]                                   Sedation quality                                                                                                                 Loading dose of 1 µg/kg in 10 minutes followed by a 0.5 µg/kg/h infusion                                                                                                After induction of general anaesthesia                                     After stabilization of haemodynamics in the ICU
  Leino K [@pone.0082913-Leino1]                                        Renal effects                      Five-step infusion of 4 µg/ml with the following decreasing infusion rate: 39 ml/h for 20 min, 24.5 ml/h for 40 min, 14 ml/h for 60 min, 10.5 ml/h for 120 min and then 7 ml/h (rates needed to achieve a pseudo steady-state plasma concentration of 0.60 µg/ml)   Immediately after anaesthesia induction                                                 4 h after ICU arrival
  Maldonado JR [@pone.0082913-Maldonado1]                             Sedation quality                                                                                                                          Loading dose of 0,4 µg/kg followed by 0.2--0.7 µg/kg/h                                                                                                                    After CPB weaning                                                                Maximum 24 h
  Martin E [@pone.0082913-Martin1]                                    Sedation quality                                                                                    Loading dose of 1 µg/kg in 10 min followed by 0.4 µg/kg/h. The latter rate could be adjusted within the range of 0.2 to 0.7 µg/kg/h                                                                     Within 1 hour after ICU admission                             For a minimum of 6 hours post extubation; total time was \<24 hours
  Memis D [@pone.0082913-Memis1]                                      Gastric emptying                                                                                                               Loading dose of 2.5 µg/kg in 10 min followed by 0.2 µg kg/h over 5 h infusion                                                                                               Within 4 hours after ICU admission                                                           5 hours
  Memis D [@pone.0082913-Memi1]                      Inflammatory responses and gastric intramucosal pH                                                                                             Loading dose of 1 µg/kg in 10 min followed by 0.2--2.5 µg/kg over 24 h infusion                                                                                                              ICU                                                                            NA
  Memis D [@pone.0082913-Memi2]                                 Indocyanine green elimination                                                                                                       Loading dose of 1 µg/kg in 10 min followed by a maintenance of 0.2--2.5 µg/kg/h                                                                                                              NA                                                                          24 hours
  Menda F [@pone.0082913-Menda1]                      Haemodynamic response to endotracheal intubation                                                                                                                             1 µg/kg in 15 min                                                                                                                                    Anaesthesia induction                                                                   NA
  Ozkan N [@pone.0082913-Ozkan1]                      Haemodynamics and mixed venous oxygen saturation                                                                                                           Loading dose of 1 µg/kg followed by 0.2--0.4 µg/kg/h                                                                                                                   Anaesthesia induction                                                                   NA
  Pandharipande PP [@pone.0082913-Pandharipande1]                     Sedation quality                                                                                                                                           Maximum 1.5 µg/kg/hr                                                                                                                                            ICU                                                          Until extubation, for maximum 120 hours
  Reade MC [@pone.0082913-Reade1]                                     Sedation quality                                                                                                             Loading dose of 1.0 µg/kg in 20 min (if desired) followed by 0.2--0.7 µg/kg/hour                                                                                                              ICU                                        As long as clinically indicated, including following extubation if required
  Riker RR [@pone.0082913-Riker1]                                     Sedation quality                                                                                                                           Loading dose of 1 µg/kg followed by 0.2--1.4 µg/kg/h                                                                                                             Within 96 hours after intubation                                                  Extubation, 30 days maximum
  Ruokonen E [@pone.0082913-Ruokonen1]                                Sedation quality                                                                                                          0.8 µg/kg/h for 1 h and then adjusted stepwise at 0.25, 0.5, 0.8, 1.1, and 1.4 µg/kg/h                                                                                           Within 72 hours after ICU admission                                                      Maximum 14 days
  Sahin N [@pone.0082913-Sahin1]                             Sedation quality and haemodynamics                                                                                                                   0.4 µg/kg/h intraoperative; 0.2--0.4 µg/kg/h in ICU                                                                                                                   Anesthesia induction                                                         45 hours after extubation
  Shehabi Y [@pone.0082913-Shehabi1]                                  Sedation quality                                                                                                                                             0.1--0.7 µg/kg/ml                                                                                                                              Within 1 hour after ICU admission                                          Removal of chest drains, maximum 48 hours
  Tasdogan M [@pone.0082913-Tasdogan1]               Inflammatory responses and intra abdominal pressure                                                                                                    Loading dose of 1 µg/kg in 10 min followed by 0.2--2.5 µg/kg/h                                                                                                                   ICU arrival                                                                     24 hours
  Terao Y [@pone.0082913-Terao1]                                      Sedation quality                                                                                                                    Loading dose of 0.1 µg/kg/min in 10 minutes followed by 0.4 µg/kg/h                                                                                                                ICU arrival                                                            First postoperative morning
  Triltsch AE [@pone.0082913-Triltsch1]                               Sedation quality                                                                                                                     Loading dose of 6 µg/kg/h in 10 min followed by 0.1--0.7 µg/kg/h                                                                                                       Within 1 hour after ICU admission                                      6--7 hours after extubation, maximum overall 72 h
  Venn RM [@pone.0082913-Venn1]                                       Sedation quality                                                                                                                         Loading dose of 2,5 µg/kg/h followed by 0,2--2,5 µg/kg/h                                                                                                                      ICU arrival                                                                    Extubation
  Wan LJ [@pone.0082913-Wan1]                                         Sedation quality                                                                                                                                                    NA                                                                                                                                                     NA                                                                             NA
  Yao L [@pone.0082913-Yao1]                                          Sedation quality                                                                                                                      Loading dose of 1 µg/kg in 10 min followed by 0.2--0.7 µg/kg/h                                                                                                                       NA                                                                             NA

ICU: Intensive Care Unit; CPB: cardiopulmonary bypass; NA: not available.

The secondary endpoint was mortality rate at the longest follow-up available. Adverse effects (hypotension and bradycardia as per author definition) were also analysed. Further endpoints included the number of patients requiring rescue doses of analgesic (opioids) or sedative (propofol, benzodiazepines, or any antipsychotics) drugs and the number of patients completely comfortable during ICU stay.

The internal validity and risk of bias of included trials was appraised by two independent reviewers according to the latest version of the "Risk of bias assessment tool" developed by The Cochrane collaboration [@pone.0082913-Higgins1], with divergences resolved by consensus. Publication bias was assessed by visually inspecting funnel plots and scatter plots and by analytical appraisal based on the Egger\'s linear regression test and on the Peters\' test for asymmetry. According to the Egger [@pone.0082913-Begg1] or Peters [@pone.0082913-Peters1] methods for publication bias evaluation, a two-sided p value of 0.10 or less was regarded as significant.

Data Analysis and Synthesis {#s2d}
---------------------------

Computations were performed with Stata release 11, College Station, TX) and SAS 2002--08 program (release 9.2, SAS Institute, Inc, Cary, NC). Hypothesis of statistical heterogeneity was tested by means of Cochran Q test, with statistical significance set at the two-tailed 0.10 level, whereas extent of statistical consistency was measured with I^2^, defined as 100%×(Q-df)/Q, where Q is Cochran\'s heterogeneity statistic and df the degrees of freedom. Binary outcomes from individual studies were analysed to compute individual and pooled risk ratio (RR) with pertinent 95% confidence interval (CI), by means of inverse variance method and with a fixed-effect model in case of low statistical inconsistency (I^2^\<25%) or with random-effect model (which better accommodates clinical and statistical variations) in case of moderate or high statistical inconsistency (I^2^\>25%). Standardized mean differences (SMD), or weighted mean difference (WMD), and 95% confidence intervals were computed for continuous variables using the same models as just described. To evaluate if the small study effect had an influence on the treatment effect estimate, in case of evidence of between-study heterogeneity (I^2^\>25), we compared the results of both fixed and random effect models. Sensitivity analyses were performed by sequentially removing each study and reanalysing the remaining dataset (producing a new analysis for each study removed) and by analysing only data from blinded studies and studies with low risk of bias.

Statistical significance was set at the two-tailed 0.05 level for hypothesis testing. Unadjusted p values are reported throughout. This study was performed in compliance with The Cochrane Collaboration and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines [@pone.0082913-Higgins1], [@pone.0082913-BiondiZoccai1], [@pone.0082913-Liberati1] ([Checklist S1](#pone.0082913.s001){ref-type="supplementary-material"}).

Results {#s3}
=======

Study Characteristics {#s3a}
---------------------

Database searches, snowballing, and contacts with experts yielded a total of 573 articles. The flow chart to select the final 27 manuscripts (28 trials) [@pone.0082913-AbdAziz1]--[@pone.0082913-Sahin1], [@pone.0082913-Corbett1]--[@pone.0082913-Venn1] is detailed in [figure 1](#pone-0082913-g001){ref-type="fig"}, with major exclusions available in the supplemental material ([Texts S2](#pone.0082913.s012){ref-type="supplementary-material"} and [S3](#pone.0082913.s013){ref-type="supplementary-material"}).

![Flow diagram.\
The flow chart to select the final 27 manuscripts (28 trials).](pone.0082913.g001){#pone-0082913-g001}

The 27 included manuscripts randomized 3,648 patients (1,870 to dexmedetomidine and 1,778 to control) ([tables 1](#pone-0082913-t001){ref-type="table"} and [2](#pone-0082913-t002){ref-type="table"}). Clinical heterogeneity was mostly due to setting, control treatment, and follow-up duration. Indeed, 13 trials used dexmedetomidine in a general ICU setting [@pone.0082913-Jakob1], [@pone.0082913-Wan1], [@pone.0082913-Yao1], [@pone.0082913-Martin1]--[@pone.0082913-Memi2], [@pone.0082913-Pandharipande1]--[@pone.0082913-Ruokonen1], [@pone.0082913-Triltsch1], ten in cardiac surgery ICU patients [@pone.0082913-AbdAziz1], [@pone.0082913-Leino1], [@pone.0082913-Menda1], [@pone.0082913-Khalil1], [@pone.0082913-Sahin1], [@pone.0082913-Corbett1], [@pone.0082913-Herr1], [@pone.0082913-Maldonado1], [@pone.0082913-Ozkan1], [@pone.0082913-Shehabi1], four in major non-cardiac surgery ICU patients [@pone.0082913-Terao1], [@pone.0082913-Elbaradie1], [@pone.0082913-Tasdogan1], [@pone.0082913-Venn1] and one after caesarean section-eclampsia admitted to ICU [@pone.0082913-Esmaoglu1]. Different techniques of dexmedetomidine administration were used: in 18 trials the continuous infusion was preceded by a loading dose that was often 1 mcg/kg [@pone.0082913-Yao1], [@pone.0082913-Khalil1], [@pone.0082913-Begg1], [@pone.0082913-Esmaoglu1], [@pone.0082913-Herr1], [@pone.0082913-Martin1], [@pone.0082913-Memi1]--[@pone.0082913-Ozkan1], [@pone.0082913-Reade1], [@pone.0082913-Riker1], [@pone.0082913-Tasdogan1] but that varied between 0.1 to 6 mcg/kg in other trials [@pone.0082913-Terao1], [@pone.0082913-Elbaradie1], [@pone.0082913-Maldonado1], [@pone.0082913-Memis1], [@pone.0082913-Ozkan1], [@pone.0082913-Ruokonen1], [@pone.0082913-Triltsch1], [@pone.0082913-Venn1]. In other 6 trials only continuous infusion was used and ranged between 0.1 to 2.5 mcg/kg/h [@pone.0082913-AbdAziz1]--[@pone.0082913-Leino1], [@pone.0082913-Sahin1], [@pone.0082913-Pandharipande1], [@pone.0082913-Shehabi1] while in one trial only the loading dose was used [@pone.0082913-Menda1] and one trial gave no details [@pone.0082913-Wan1]. Study quality appraisal indicated that trials were of medium quality ([Table S1](#pone.0082913.s006){ref-type="supplementary-material"}); in particular 12of them had a low risk of bias.

Six different comparators were identified: propofol in 11 study arms [@pone.0082913-Jakob1], [@pone.0082913-Terao1], [@pone.0082913-Begg1], [@pone.0082913-Elbaradie1], [@pone.0082913-Herr1], [@pone.0082913-Maldonado1], [@pone.0082913-Memis1], [@pone.0082913-Memi2], [@pone.0082913-Ruokonen1], [@pone.0082913-Tasdogan1], [@pone.0082913-Venn1], midazolam in 10 arms [@pone.0082913-Jakob1], [@pone.0082913-Wan1], [@pone.0082913-Yao1], [@pone.0082913-Sahin1], [@pone.0082913-Esmaoglu1], [@pone.0082913-Maldonado1], [@pone.0082913-Memi1], [@pone.0082913-Ozkan1], [@pone.0082913-Riker1], [@pone.0082913-Ruokonen1], placebo in 5 arms [@pone.0082913-Leino1], [@pone.0082913-Menda1], [@pone.0082913-Khalil1], [@pone.0082913-Martin1], [@pone.0082913-Triltsch1], morphine in 2 arms [@pone.0082913-AbdAziz1], [@pone.0082913-Shehabi1], haloperidol [@pone.0082913-Reade1] and lorazepam [@pone.0082913-Pandharipande1] in one study.

Quantitative Data Synthesis {#s3b}
---------------------------

### Effect of dexmedetomidine on ICU stay and time to extubation {#s3b1}

Overall analysis ([figure 2](#pone-0082913-g002){ref-type="fig"}; [figure S1](#pone.0082913.s002){ref-type="supplementary-material"}) showed that the use of dexmedetomidine was associated with a significant reduction in length of ICU stay (WMD = −0.79 \[−1.17 to −0.40\] days, p for effect \<0.001, p for heterogeneity\<0.001,I^2^ = 93%, SMD = −0.48 \[−0.78 to −0.18\], p for effect  = 0.002, p for heterogeneity \<0.001, I^2^ = 91%; with 17 studies and 2,424 patients included) with results confirmed when subanalyses were performed on studies including patients undergoing elective surgery (SMD = −0.60 \[−1.05 to −0.15\], p for effect = 0.008 with 8 studies included), in those including patients undergoing short term sedation (SMD = −0.45 \[−0.81 to −0.09\], p for effect = 0.02 with 11 studies included), in those including patients receiving a loading dose (SMD = −0.58 \[−1.03 to −0.13\], p for effect = 0.01 with 11 studies included) and in those receiving low (\<0.7 µg kg−1 h−1) maintenance dose of dexmedetomidine (SMD = −0.62 \[−1.04 to −0.20\], p for effect = 0.004 with 10 studies included) as detailed in [table 3](#pone-0082913-t003){ref-type="table"}.

![Forest plot for the length of ICU stay.\
Overall analysis showed that the use of dexmedetomidine was associated with a significant reduction in length of ICU stay (SMD = −0.48 \[−0.78 to −0.18\] , p for effect = 0.002, p for heterogeneity \<0.001, I2 = 91% with 17 studies and 2,424 patients included). ICU = intensive care unit; CI = confidence interval; SMD = standardized mean difference; N = number; SD = standard deviation; Dex = dexmedetomidine.](pone.0082913.g002){#pone-0082913-g002}

10.1371/journal.pone.0082913.t003

###### Sensitivity analyses of intensive care unit stay and time to extubation.

![](pone.0082913.t003){#pone-0082913-t003-3}

  Outcome                                                                                                                             Number of included trials       Dex patients   Controlpatients      SMD            95% CI         P for effect   P for heterogeneity   I^2^ (%)
  ------------------------------------------------------------------------------------------------------------------------------ ----------------------------------- -------------- ----------------- ----------- -------------------- -------------- --------------------- ----------
  **ICU stay**                                                                                                                                 **17**                  **1,274**        **1,150**      **−0.48**   **−0.78 to −0.18**    **0.002**         **\<0.001**        **91**
  -Postoperative elective surgery patients                                                                                                        8                       373              372           −0.60       −1.05 to −0.15        0.008             \<0.001            86
  \-\-\-- Cardiac surgery                                                                                                                         6                       337              336           −0.57       −1.11 to −0.03         0.04             \<0.001            89
  \-\-\-- CABG surgery                                                                                                                            4                       103              106           −0.76       −1.94 to 0.42          0.2              \<0.001            93
  \-\-\-- Non Cardiac surgery                                                                                                                     2                        36              36            −0.75       −1.23 to −0.27        0.002               0.3              23
  -ICU patients (non elective postoperative)                                                                                                      9                       901              778           −0.38       −0.82 to 0.06          0.09             \<0.001            93
  -excluding outlier studies [@pone.0082913-Khalil1], [@pone.0082913-Reade1], [@pone.0082913-Riker1]                                             13                       1438            1427           −0.17       −0.29 to −0.05        0.005              0.15              28
  \- Long term sedation                                                                                                                           6                       849              726           −0.54       −1.09 to 0.008        0.053             \<0.001            95
  \- Short term sedation                                                                                                                         11                       425              424           −0.45       −0.81 to −0.09         0.02             \<0.001            82
  \- Daily interruption sedation                                                                                                                  5                       839              716           −0.38       −0.96 to 0.18          0.18             \<0.001            96
  \- High maintenance dose                                                                                                                        7                       879              756           −0.31       −0.79 to 0.17          0.2              \<0.001            95
  \- Low maintenance dose(\<0.7 µg kg−1 h−1)                                                                                                     10                       395              394           −0.62       −1.04 to −0.20        0.004             \<0.001            85
  \- Loading dose                                                                                                                                11                       281              282           −0.58       −1.03 to −0.13         0.01             \<0.001            83
  \- No loading dose                                                                                                                              6                       993              868           −0.36       −0.81 to 0.10          0.13             \<0.001            96
  \- Loading dose and high maintenance dose                                                                                                       2                       140              40            −0.09       −0.79 to 0.61          0.8               0.12              60
  \- SENSITIVITY (including only blinded studies)                                                                                                 8                       891              768           −0.56       −1.09 to −0.04         0.04             \<0.001            95
  SENSITIVITY (including only low risk of bias studies)                                                                                          10                       1065             940           −0.44       −0.86 to −0.02         0.04             \<0.001            94
  SENSITIVITY (removing 1 study at time)                                                                                          All 95% CIs of SDM\<0 and p\<0.05                                                                                                         
  SMALL STUDY EFFECT (fixed model)                                                                                                                                                                       −0.34       −0.43 to −0.26       \<0.001                           
  **Time to extubation**                                                                                                                       **24**                  **1,804**        **1,674**      **−0.39**   **−0.66 to −0.11**    **0.005**         **\<0.001**        **93**
  -Postoperative elective surgery patients                                                                                                       17                       954              942           −0.31       −0.52 to −0.09        0.005             \<0.001            77
  \-\-\-- Cardiac surgery                                                                                                                        10                       558              555           −0.42       −0.75 to −0.10         0.01             \<0.001            83
  \-\-\-- CABG surgery                                                                                                                            7                       310              311           −0.59       −1.13 to −0.05         0.03             \<0.001            89
  \-\-\-- Non Cardiac surgery (3 studies did not specify the operative setting)                                                                   4                        76              76            −0.15       −0.47 to 0.17          0.4                0.8              0
  -ICU patients (non elective postoperative)                                                                                                      7                       850              732           −0.52       −1.25 to 0.21          0.16             \<0.001            97
  -excluding outlier studies [@pone.0082913-Khalil1], [@pone.0082913-Reade1], [@pone.0082913-Riker1]                                             20                       995              993           −0.16       −0.26 to −0.05        0.003              0.04              39
  \- Long term sedation                                                                                                                           6                       830              712           −0.65       −1.44 to 0.15          0.11             \<0.001            98
  \- Short term sedation                                                                                                                         18                       974              962           −0.28       −0.49 to −0.07        0.009             \<0.001            76
  \- Daily interruption sedation                                                                                                                  4                       785              664           −0.69       −1.70 to 0.32          0.18             \<0.001            99
  \- High maintenance dose                                                                                                                        7                       859              737           −0.42       −1.13 to 0.30          0.3              \<0.001            76
  \- Low maintenance dose(\<0.7 µg kg−1 h−1)                                                                                                     16                       843              839           −0.30       −0.53 to −0.07        0.009             \<0.001            76
  \- Loading dose                                                                                                                                16                       734              731           −0.23       −0.47 to 0.001        0.051             \<0.001            75
  \- No loading dose                                                                                                                              7                       968              845           −0.60       −1.25 to 0.05          0.07             \<0.001            97
  \- Loading dose and high maintenance dose                                                                                                       3                        74              73            −0.08       −0.44 to 0.27          0.3                0.3              11
  SENSITIVITY (including only blinded studies)                                                                                                   10                       1241            1112           −0.56       −1.06 to −0.05         0.03             \<0.001            97
  SENSITIVITY (including only low risk of bias studies)                                                                                           8                       1023             899           −0.72       −1.34 to −0.10         0.02             \<0.001            97
  SENSITIVITY (removing 1 study at time)                                                                                          All 95% CIs of SDM\<0 and p\<0.05                                                                                                         
  SENSITIVITY(Jakob study [@pone.0082913-Jakob1] included as time on mechanical ventilation) [\*](#nt105){ref-type="table-fn"}                   24                      1,804            1,674          −0.38       −0.66 to −0.10        0.007             \<0.001            93
  SMALL STUDY EFFECT (fixed model)                                                                                                                                                                       −0.31       −0.38 to 0.24        \<0.001                           

The overall analyses using weighted mean differences showed a reduction in intensive care unit stay of −0.79 \[−1.17 to −0.40\] days and a reduction in time to extubation of −2.74 \[−3.80 to −1.65\] hours in the dexmedetomidine group. It should be noted that the standard mean differences used in this table is not expressed in days or hours.

Dex: dexmedetomidine; SMD: standardized mean difference; CI: confidence interval; P: p-value; CABG: coronary artery bypass grafting; ICU: intensive care unit; NIV: non invasive ventilation.

duration of mechanical ventilation from randomization until patients were free of mechanical ventilation(including noninvasive).

The use of dexmedetomidine was also associated ([figure 3](#pone-0082913-g003){ref-type="fig"}; [figure S2](#pone.0082913.s003){ref-type="supplementary-material"}) with a significant reduction of time to extubation (WMD = −2.74 \[−3.80 to −1.65\] hours, p for effect \<0.001, p for heterogeneity\<0.001,I^2^ = 96%, SMD = −0.39 \[−0.66 to −0.11\], p for effect = 0.005, p for heterogeneity \<0.001, I^2^ = 93% with 24 studies and 3,478 patients included). Further subanalyses, detailed in [table 3](#pone-0082913-t003){ref-type="table"}, confirmed these findings in patients receiving short term sedation (SMD = −0.28 \[−0.49 to −0.07\], p for effect = 0.009 with 18 studies included), in those receiving a low (\<0.7 µg kg−1 h−1) maintenance dose (SMD = −0.30 \[−0.53 to −0.07\], p for effect = 0.009 with 16 studies included) and in those undergoing elective surgery (SMD = −0.31 \[−0.52 to −0.09\], p for effect = 0.005 with 17 studies included) with most of the positive finding coming from the cardiac surgery setting (SMD = −0.42 \[−0.75 to −0.10\], p for effect = 0.01 with 10 studies included). The largest study [@pone.0082913-Jakob1] included in this meta-analysis was also the only one to report both median and mean values for mechanical ventilation. Since these data were skewed, we repeated the analyses including median instead of mean values and didn\'t find differences in pooled estimate results (SMD = −0.39, 95% CI −0.66 to −0.12, I-square = 93%).

![Forest plot for the time to extubation.\
Overall analysis showed that the use of dexmedetomidine was associated with a significant reduction of time to extubation (SMD = −0.39 \[−0.66 to −0.11\], p for effect = 0.005, p for heterogeneity \<0.001, I2 = 93% with 24 studies and 3,478 patients included). CI = confidence interval; SMD = standardized mean difference; N = number; SD = standard deviation; Dex = dexmedetomidine.](pone.0082913.g003){#pone-0082913-g003}

Further subanalyses with the different comparators (propofol, midazolam, placebo and morphine) are detailed in supplemental material ([TableS2](#pone.0082913.s007){ref-type="supplementary-material"} [Table S3](#pone.0082913.s008){ref-type="supplementary-material"}, [Table S4](#pone.0082913.s009){ref-type="supplementary-material"} and [Table S5](#pone.0082913.s010){ref-type="supplementary-material"}) but were not informative with respect to ICU stay or time to extubation due to the paucity of trials included.

Visual inspection of funnel and scatter plots ([figures 4](#pone-0082913-g004){ref-type="fig"} and [5](#pone-0082913-g005){ref-type="fig"}; [figures S3](#pone.0082913.s004){ref-type="supplementary-material"} and [S4](#pone.0082913.s005){ref-type="supplementary-material"}) did not identify a skewed or asymmetrical shape for the co-primary endpoints. Quantitative evaluation did not suggest a presence of publication bias, as measured by the Egger\'s test (p = 0.4 for the length of ICU stay and p = 0.5 for time to extubation) and Peters\' test (p = 0.6 for the length of ICU stay and p = 0.9 for time to extubation). Since the funnel plots identified three outlier studies [@pone.0082913-Khalil1], [@pone.0082913-Reade1], [@pone.0082913-Riker1] we repeated the analyses removing them and found that the statistically significant difference in ICU stay and time to extubation was maintained (p = 0.005 and p = 0.003 respectively ) and the heterogeneity reduced (I^2^ = 28% and I^2^ = 39% respectively ) ([table 3](#pone-0082913-t003){ref-type="table"}).

![Funnel plot for the length of ICU stay.\
Visual inspection of funnel plots did not identify a skewed or asymmetrical shape for the co-primary endpoints. Quantitative evaluation did not suggest a presence of publication bias, as measured by the Egger\'s test (p = 0.4) and Peters\' test (p = 0.6). ICU = intensive care unit; SE = standard error; SMD = standardized mean difference.](pone.0082913.g004){#pone-0082913-g004}

![Funnel plot for the time to extubation.\
Visual inspection of funnel plots did not identify a skewed or asymmetrical shape for the co-primary endpoints. Quantitative evaluation did not suggest a presence of publication bias, as measured by the Egger\'s test (p = 0.5) and Peters\' test (p = 0.9). SE = standard error; SMD =  standardized mean difference.](pone.0082913.g005){#pone-0082913-g005}

### Effect of dexmedetomidine on rescue doses of analgesic drugs, incidence of bradycardia, hypotension and mortality {#s3b2}

Rescue doses of sedative or analgesic drugs were required less in the dexmedetomidine patients (892/1,459 \[61%\] in the dexmedetomidine group versus 977/1,366 \[72%\] in the control arm, p = 0.01 with 14 studies included). A subanalysis showed that dexmedetomidine was associated with a significant reduction in the number of patients requiring rescue doses of analgesic drugs (691/927 \[67%\] in the dexmedetomidine group versus 624/802 \[78%\] in the control arm, RR = 0.80 \[0.66 to 0.98\], p = 0.03) with no differences in the number of patients requiring rescue doses of sedative drugs (271/532 \[51%\] in the dexmedetomidine group versus 353/564 \[63%\] in the control arm, p = 0.3) ([Table 4](#pone-0082913-t004){ref-type="table"}).

10.1371/journal.pone.0082913.t004

###### Secondary Outcomes.

![](pone.0082913.t004){#pone-0082913-t004-4}

  Outcome                                                                  Number of included trials     Dex patients      Control patients     RR       95% CI      P for effect   P for heterogeneity   I^2^ (%)
  ----------------------------------------------------------------------- --------------------------- ------------------- ------------------- ------ -------------- -------------- --------------------- ----------
  **Mortality**                                                                       20               200/1,499 \[13%\]   173/1,409 \[12%\]   1.00   0.84 to 1.21       0.9                0.9              0
  **Hypotension**                                                                     19               424/1,389 \[31%\]   279/1,266 \[22%\]   1.27   1.00 to 1.61      0.052             \<0.001            62
  **Bradycardia**                                                                     17               220/1,374 \[16%\]    64/1,246 \[5%\]    2.43   1.88 to 3.14     \<0.001              0.9              0
  **Patients requiring rescue doses of either sedatives or analgesics**               14               892/1,459 \[61%\]   977/1,366 \[72%\]   0.81   0.70 to 0.95       0.01             \<0.001            84
  \-\--requiring sedative drugs                                                        8                271/532 \[51%\]     353/564 \[63%\]    0.84   0.62 to 1.14       0.3              \<0.001            82
  \-\--requiring analgesic drugs                                                       6                621/927 \[67%\]     624/802 \[78%\]    0.80   0.66 to 0.98       0.03             \<0.001            88
  **Number of patients completely comfortable**                                        3                112/253 \[44%\]    103/254 \[40.6%\]   1.07   0.49 to 2.49       0.9               0.003             82

Dex: dexmedetomidine; RR: relative risk; CI: confidence interval; P: p-value.

Dexmedetomidine was associated with an increased rate of bradycardia (220/1,374 \[16%\] in the dexmedetomidine group vs 64/1,246 \[5%\] in the control group, RR = 2.43\[1.88 to 3.14\], p for effect \<0.001, p for heterogeneity = 0.9, I^2^ = 0% with 17 studies included) and with a trend towards an increased rate of hypotension (424/1,389 \[31%\] in the dexmedetomidine group vs 279/1,266 \[22%\] in the control group, RR = 1.27\[1.00 to 1.61\], p for effect 0.052, p for heterogeneity \<0.001, I^2^ = 62% with 19 studies included) ([Table 4](#pone-0082913-t004){ref-type="table"}).

No difference in mortality was recorded at the longest follow-up available (200/1,499 \[13%\] in the dexmedetomidine group vs 173/1,409 \[12%\] in the control group, RR = 1.00 \[0.84 to 1.21\], p for effect = 0.9 with 20 studies included). The univariate meta-regression of average follow-up against log-risk mortality showed no significant effects for time on mortality (n = 20, slope coefficient = −0.001 \[−0.003 to 0.001\], p = 0.31) ([Table 4](#pone-0082913-t004){ref-type="table"}).

Sensitivity analyses {#s3c}
--------------------

Estimate results from both random and fixed effect models were extremely similar ([table 3](#pone-0082913-t003){ref-type="table"}); hence we excluded a considerable small study effect. Sensitivity analyses performed by sequentially removing each study and reanalysing the remaining dataset (producing a new analysis for each study removed), did not determine major changes in direction or magnitude of statistical findings, confirming the pooled effect of each co-primary endpoints (all SWD\<1) and the statistical significance (all p of effect \<0 .05). Sensitivity analyses carried out with studies with low risk of bias confirmed the overall results of our work showing a reduction in length of ICU stay in dexmedetomidine versus control group (SMD = −0.44 \[−0.86 to −0.02\] p for effect = 0.04, p for heterogeneity \<0.001, I^2^ = 94% with 10 studies and 2,005 patients included) and in time to extubation (SMD = −0.72 \[−1.34 to −0.10\], p for effect = 0.02, p for heterogeneity \<0.001, I^2^ = 97% with 8 studies and 1,922 patients included). Sensitivity analyses carried out with blinded studies confirmed the overall results of our work showing a reduction in length of ICU stay in dexmedetomidine versus control group (SMD = −0.56 \[−1.09 to −0.04\], p for effect = 0.04, p for heterogeneity \<0.001, I^2^ = 95% with 8 studies and 1,659patients included) and a reduction in time to extubation (SMD = −0.56 \[−1.06 to 0.05\], p for effect = 0.03, p for heterogeneity \<0.001, I^2^ = 97% with 10 studies and 2,353 patients included).

Discussion {#s4}
==========

Our meta-analysis confirmed that dexmedetomidine is associated with a reduction in ICU stay and suggested that it might reduce the time of extubation when compared to other sedative or hypnotic agent. Even if dexmedetomidine is associated with an increase in the risk of bradycardia and with a trend toward an increased risk of hypotension, no detrimental effects on mortality were detected.

The ideal sedative agent should provide anticipated, predictable effects, rapid onset, and quick recovery. It should be easy to administer with no adverse events, no interaction with other drugs, no accumulation of metabolites and no withdrawal effects at the end of infusion. Unluckily an ideal sedative agent that can suit the need of all patients does not yet exist.

Dexmedetomidine is one of the most recently released intravenous agents for sedation in the ICU, though the drug started to be investigated more than 20 years ago. It was introduced in clinical practice in the United States in 1999 while the European Medicine Agency authorised its use for all 27 European member states in September 2011. It is an alpha2-agonist and produces sedation acknowledged as "cooperative" or "arousable", which is different from the sedation "clouding of consciousness" induced by drugs acting on GABA receptors, such as midazolam or propofol [@pone.0082913-Aho1]. Tan and Ho, in a previous meta-analysis updated on December 2009 [@pone.0082913-Tan1] reported that when dexmedetomidine was compared with alternative sedative agents it was associated with a statistically significant reduction in length of ICU stay, but not in duration of mechanical ventilation. We updated their findings on February 2013 identifying eight recently published manuscripts [@pone.0082913-AbdAziz1]--[@pone.0082913-Khalil1] and one trial that was not identified in their systematic search [@pone.0082913-Sahin1], thus increasing the number of patients by 50% (up to 3,648 overall randomized patients included in our meta-analysis) and providing more robust safety data. By adding more patients data we were able to show, for the first time in a meta-analysis, that dexmedetomidine increases the rate of bradycardia when all trials are pooled together and also shows a trend towards an increase rate of hypotension. However, these side effects were not associated with differences in mortality (200/1499 \[13%\] in the dexmedetomidine group vs 173/1409 \[12%\] in the control group, p = 0.9 with 20 studies included).

Dexmedetomidine decreases sympathetic nervous system activity and is therefore associated with an increase in cardiovascular adverse events. These effects may be most pronounced in patients with decreased autonomic nervous system response such as the elderly, diabetic patients, patients with chronic hypertension or severe cardiac disease such as valve stenosis or regurgitation, advanced heart block, severe coronary artery disease, or in patients who are already hypotensive and/or hypovolemic [@pone.0082913-Gertler1]. Therefore, in patients who depend on a high level of sympathetic tone or in patients with reduced myocardial function who cannot tolerate the decrease in sympathetic tone, loading doses of dexmedetomidine should be avoided. On the other side, the characteristics of dexmedetomidine to provide an ongoing sedation and sympathetic block could be beneficial in reducing early postoperative ischemic events in high-risk patients [@pone.0082913-Talke1]--[@pone.0082913-Chorney1].

Intravenous administration of dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with an half-life (t 1/2 α) of 6 min, a terminal elimination half-life (t 1/2 β) of 2 hours, and a steady-state volume of distribution (Vss) of 118 litres. It presents linear kinetics when infused in the range of 0.2--0.7 µg/kg/h for no more than 24 hours and undergoes almost complete biotransformation through direct glucuronidation and cytochrome P450 metabolism. Consequently it can accumulate in patients who are on P450 enzyme inhibitors, some of which are commonly used in ICU. Metabolites of biotransformation are excreted in the urine (95%) and faeces [@pone.0082913-YazbekKaram1].

Limitations {#s4a}
-----------

We acknowledge that this study has several limitations. The quality of the included studies is not high since only 13 of them were blind. Moreover we noted high heterogeneity between the included studies. The heterogeneity remained when sensitivity analyses on studies with low risk of bias where performed. It was abolished only removing three outliers studies cited above. Nonetheless we excluded the possible influence of small-study effects on the results of our meta-analysis comparing the fixed- and random-effects estimates of the treatment effect ([table 3](#pone-0082913-t003){ref-type="table"}). The overall reduction in ICU stay and time to extubation may appear clinically modest, but it should be acknowledged that the largest study [@pone.0082913-Jakob1] had very conservative imputation rules (to worst outcome) and this might have softened our results.

Conclusions {#s5}
===========

Dexmedetomidine for sedation in mechanically ventilated critically ill adult patients seems to help to reduce time to extubation and ICU stay. The known side effects (increased incidence of bradycardia and a trend toward an increased risk of hypotension) had no effect on the overall mortality in this meta-analysis of all the RCTs published so far.

Larger, multicentre, randomized clinical trials, especially in long term sedated patients requiring mechanical ventilation, would be welcome to confirm these findings.
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